Show simple item record

dc.contributor.authorDahal, Shishir
dc.contributor.authorAllette, Yohance Mandela 
dc.contributor.authorNaunton, Kerry
dc.contributor.authorHarrison, Daniel M.
dc.date.accessioned2023-02-16T16:18:20Z
dc.date.available2023-02-16T16:18:20Z
dc.date.issued2023-02-20
dc.identifier.urihttp://hdl.handle.net/10713/20376
dc.descriptionPoster presented at the NAIMS workshop and ACTRIMS meeting, February 20, 2023.en_US
dc.language.isoen_USen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subject.meshPilot Projectsen_US
dc.subject.meshAntibodies, Monoclonal, Humanizeden_US
dc.subject.meshMultiple Sclerosisen_US
dc.subject.meshMeninges--pathologyen_US
dc.titleA Pilot Trial of Ocrelizumab for Modulation of Meningeal Enhancement in Multiple Sclerosisen_US
dc.typePoster/Presentationen_US
refterms.dateFOA2023-02-16T16:18:21Z


Files in this item

Thumbnail
Name:
Dahal_A-Pilot-of-Ocrelizumab_2 ...
Size:
745.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International